Cautious. JBIO's weak Value Compounder Score (26/100) signals modest profitability and capital efficiency, while moderate Leadership Alignment (61/100) offers limited confidence in capital allocation. The Vulnerability Index registers at maximum (100/100), flagging unquantified structural or operational risks that materially constrain conviction until clarity emerges.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Jade Biosciences, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 45/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Jade Biosciences, Inc. (JBIO) at 45/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. JBIO's weak Value Compounder Score (26/100) signals modest profitability and capital efficiency, while moderate Leadership Alignment (61/100) offers limited confidence in capital allocation. The Vulnerability Index registers a
JBIO's current Stocky Verdict is 45/100, placing it in the "Cautious" band. This composite combines a 26/100 Compounder score, 61/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Jade Biosciences, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Jade Biosciences, Inc. scores 61/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Jade Biosciences, Inc.'s Vulnerability Profile scores 100/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Jade Biosciences, Inc..
Sign up free and unlock the full analysis on JBIO — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for JBIO in the app.
